Inventaire - your friends and communities are your best library

Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib

author

Laurent Yvan-Charvet

1978 -

published in: Arteriosclerosis, Thrombosis, and Vascular Biology

date of publication: 2010-05-06

language: English

main subject: lipoprotein, niacinamide

Cites articles 54

Date

Title

Authors

2009-10-01

Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses

Laurent Yvan-Charvet
2009-02

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
2009-07-01

Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
2009-03-26

Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells
2008-11-26

Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway

FOURNIER, Wilfried le Goff
2008-11-01

Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors

Christie M. Ballantyne
2008-10-27

The role of dysfunctional HDL in atherosclerosis
2008-10-13

Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions

Laurent Yvan-Charvet
2008-09-30

Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux

Michael C. Phillips
2008-06-14

Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages
2008-06-09

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
2008-05-01

HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis

Laurent Yvan-Charvet
2008-03-28

Laboratory assessment of HDL heterogeneity and function
2008-02-01

The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis
2008-03-01

Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins
2008-02-01

Is raising HDL a futile strategy for atheroprotection?

Robert A. Hegele
2008-11-24

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc

Danielle M Brennan, Steven Nissen, E. Murat Tuzcu, Jean-Claude Tardif
2008-07-10

High-density lipoprotein reduces the human monocyte inflammatory response.

Kevin J Woollard
2007-10-01

The role of myeloperoxidase in HDL oxidation and atherogenesis
2007-11-01

New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease

Rajesh Puranik
2007-11-22

Effects of torcetrapib in patients at high risk for coronary events

Michel Komajda
2007-03-26

Effect of torcetrapib on the progression of coronary atherosclerosis

Stephen Nicholls, Witold Rużyłło, Steven Nissen, E. Murat Tuzcu, Jean-Claude Tardif
2007-03-01

Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL

Sina A Gharib, Andrew N Hoofnagle, Paul Ridker, Santica M Marcovina
2007-02-01

Mechanisms of disease: HDL metabolism as a target for novel therapies
2007-12-21

Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia

Christie M. Ballantyne
2007-12-01

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies
2007-11-05

Illuminating HDL--is it still a viable therapeutic target?
2007-08-29

The roles of different pathways in the release of cholesterol from macrophages.

Francesca Zimetti, Michael C. Phillips
2007-02-22

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

Laurent Yvan-Charvet
2006-05

HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway
2006-05-01

Putting cholesterol in its place: apoE and reverse cholesterol transport
2006-11-01

Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-α secretion in Abca1-deficient macrophages

Daisaku Masuda

Article - wd:Q42562376

Welcome to Inventaire

the library of your friends and communities

learn more